ClinicalTrials.gg
CompletedNCT00713609Updated Mar 6, 2017Results posted

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

A Phase 2 interventional study of Benzoyl peroxide gel and Clindamycin gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 16 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
591
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.

Enrollment
10th of 33
591 · median 90
Started
2008
with 3 others
Phase 2
2 of 33
none open now
Registered
6th of 33
by date
Lead sponsor
7 of 33
Stiefel, a GSK Company

Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 10th largest by enrollment, is one of 4 that started in 2008, is one of 2 in phase 2, and was the 6th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About Benzoyl Peroxide

Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing Benzoyl Peroxide in Acne Vulgaris as a file.
02

Study summary

Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris.

You may be suitable to take part in this study because you have acne vulgaris on your face. Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms, legs, and back.

Read the detailed description

The study subjects must have acne vulgaris and will apply study drug to their face for 12 weeks.

Study visits will occur at baseline (day 1) and at weeks 2, 4, 8, and 12. Subjects will be assessed at every visit to determine how the study drug is working. Safety will be assessed by evaluation of adverse events (AEs), vital signs, physical examinations, and withdrawals from the study.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne
  • Acne Vulgaris
  • Pimples
04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion Criteria: Subjects must be males or females 12 to 45 years of age.
  • Subjects must have acne on their face.
  • Female subjects of must have a negative pregnancy test. If sexually active, one medically acceptable forms of must be practiced from baseline to the last study visit.
  • Subjects must have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
  • Subjects must be capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements).
  • Subjects must be able to complete the study and to comply with study instructions.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are pregnant, trying to become pregnant, or breast-feeding.
  • Subjects with conditions that may influence the safety and or efficacy assessments of the study including, but not limited to: regional enteritis or inflammatory bowel disease, lupus, dermatomyositis, rosacea, seborrheic dermatitis, beard folliculitis, or perioral dermatitis, subject who are or have had any major illness within 30 days before the screening examination
  • History of known or suspected intolerance including any known or previous allergic reaction to any of the ingredients of the study products
  • Subjects who have used topical antibiotics or topical on the face, facial procedures, or any therapy within the past 4 weeks or systemic retinoids within the past 6 months.
  • Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put the subject at unacceptable risk for participation in the study.
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
591 participants (actual)

Study arms

  • Experimental
    1

    Benzoyl peroxide/clindamycin gel + tazarotene cream

    Drug: Benzoyl peroxide gel · Drug: Clindamycin gel · Drug: Tazarotene cream

  • Active comparator
    2

    Benzoyl peroxide/clindamycin gel + vehicle cream

    Drug: Benzoyl peroxide gel · Drug: Clindamycin gel · Drug: Vehicle cream

  • Active comparator
    3

    Benzoyl peroxide gel + tazarotene cream

    Drug: Benzoyl peroxide gel · Drug: Tazarotene cream

  • Active comparator
    4

    Clindamycin gel + tazarotene cream

    Drug: Clindamycin gel · Drug: Tazarotene cream

  • Active comparator
    5

    Vehicle gel+ tazarotene cream

    Drug: Tazarotene cream · Drug: Vehicle gel

  • Placebo comparator
    6

    Vehicle gel + vehicle cream

    Drug: Vehicle gel · Drug: Vehicle cream

Interventions

  • 5% benzoyl peroxide in a gel applied topically once a day

  • 1% clindamycin phosphate applied topically once a day

  • 0.1 % tazarotene in a cream applied topically once a day

  • DrugVehicle gel

    Vehicle gel is an identical gel without the active ingredients

  • DrugVehicle cream

    Vehicle cream is an identical cream without the active ingredients

06

What researchers measure

Primary outcomes

  1. Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12

    The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts \[only post-Baseline\]) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

    Time frame: Baseline and up to Week 12

  2. Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

    An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.

    Time frame: Baseline and up to Week 12

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)

    The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

    Time frame: Baseline and up to Week 12

  2. Proportion of Participants With an ISGA Score of 0 or 1 at Week 12

    An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.

    Time frame: Week 12

07

Results

Posted Mar 6, 2017

Participant flow

In this multi-center, double-blind, vehicle controlled study, participants were assigned to one of the six treatment groups in a 2:2:2:2:2:1 ratio for 12 weeks.

Participant flow — Overall Study
MilestoneBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
Started10610510710810655
Completed859092998747
Not completed2115159198
Withdrew: Adverse event202231
Withdrew: Lost to follow-up575570
Withdrew: Lack of efficacy130010
Withdrew: Non-compliance with study treatment112010
Withdrew: Withdrawal by subject615157
Withdrew: Protocol violation631120

Outcome measures

PrimaryAbsolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12

The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts \[only post-Baseline\]) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

Time frame:
Baseline and up to Week 12
Reported as:
Mean · Lesion count
Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12
Lesion countBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
ILC, n=101, 103, 105, 105, 104, 52-16.8 ± 14.35-18.1 ± 14.45-18.9 ± 12.84-18.8 ± 11.49-14.5 ± 12.76-8.96 ± 12.63
NILC, n=101, 103, 105, 105, 104, 52-33.0 ± 23.94-24.9 ± 33.41-37.1 ± 29.70-37.5 ± 29.51-33.0 ± 25.89-18.9 ± 28.41
TLC, n=101, 103, 105, 105, 104, 52-49.8 ± 31.78-43.0 ± 42.24-56.0 ± 34.99-56.3 ± 35.42-47.6 ± 33.32-27.8 ± 35.06
Statistical analysis
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = 0.692 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.467 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.281 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.075 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = <0.001 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.803 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.175 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.552 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = 0.006 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.618 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.149 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.255 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For TC)
PrimaryProportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.

Time frame:
Baseline and up to Week 12
Reported as:
Number · Percentage of participants
Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
Percentage of participantsBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 1222223136205
Statistical analysis
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.922
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.132
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.020
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.706
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.009
SecondaryPercent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)

The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

Time frame:
Baseline and up to Week 12
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)
Percent changeBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
ILC, n=101, 103, 105, 105, 104, 52-58.3 ± 45.57-62.4 ± 39.33-62.4 ± 34.83-65.7 ± 33.38-49.0 ± 40.90-33.5 ± 41.10
NILC, n=101, 103, 105, 105, 104, 52-58.0 ± 29.97-39.2 ± 51.29-60.6 ± 35.00-61.2 ± 31.60-53.1 ± 30.56-29.5 ± 44.05
TLC, n=101, 103, 105, 105, 104, 52-59.1 ± 29.96-47.9 ± 38.89-62.0 ± 29.42-63.4 ± 28.75-51.8 ± 29.18-31.5 ± 37.59
Statistical analysis
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = 0.504 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.504 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.177 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.084 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For ILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = <0.001 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.776 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.465 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.288 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For NILC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · ANCOVA · p = 0.006 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · ANCOVA · p = 0.620 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · ANCOVA · p = 0.291 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · ANCOVA · p = 0.085 (For TC)
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · ANCOVA · p = <0.001 (For TC)
SecondaryProportion of Participants With an ISGA Score of 0 or 1 at Week 12

An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Proportion of Participants With an ISGA Score of 0 or 1 at Week 12
Percentage of participantsBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
Proportion of Participants With an ISGA Score of 0 or 1 at Week 12333127392213
Statistical analysis
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide/Clindamycin + Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.652
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Benzoyl Peroxide Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.279
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Clindamycin Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.312
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Tazarotene · Cochran-Mantel-Haenszel · p = 0.063
  • Benzoyl Peroxide/Clindamycin + Tazarotene vs Vehicle Gel + Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.005

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 up to Day 89.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benzoyl Peroxide/Clindamycin + Tazarotene—0/106 (0%)25/106 (23.6%)
Benzoyl Peroxide/Clindamycin + Vehicle Cream—0/105 (0%)22/105 (21%)
Benzoyl Peroxide Gel + Tazarotene—0/107 (0%)24/107 (22.4%)
Clindamycin Gel + Tazarotene—0/108 (0%)18/108 (16.7%)
Vehicle Gel + Tazarotene—0/106 (0%)29/106 (27.4%)
Vehicle Gel + Vehicle Cream—0/55 (0%)12/55 (21.8%)
Most frequent other events
Showing 10 of 82
Most frequent other events
EventBenzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle Cream
NasopharyngitisInfections and infestations3/1063/1053/1075/1084/1063/55
Upper respiratory tract infectionInfections and infestations5/1064/1055/1072/1084/1061/55
Application site irritationGeneral disorders1/1060/1053/1074/1082/1060/55
Application site painGeneral disorders0/1060/1052/1070/1080/1062/55
SinusitisInfections and infestations1/1061/1052/1070/1081/1062/55
EpistaxisRespiratory, thoracic and mediastinal disorders0/1060/1053/1070/1080/1060/55
Application site pruritusGeneral disorders0/1060/1050/1070/1082/1061/55
Allergy to arthropod biteImmune system disorders2/1060/1050/1070/1081/1060/55
InfluenzaInfections and infestations1/1060/1050/1070/1082/1060/55
HeadacheNervous system disorders0/1060/1051/1070/1082/1060/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle CreamTotal
Mean19.7 ± 6.619.7 ± 6.920.2 ± 7.319.2 ± 6.221.7 ± 8.419.8 ± 6.620.1 ± 7.1
Gender
Gender(Participants)Benzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle CreamTotal
Female585660606535334
Male484947484120253
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benzoyl Peroxide/Clindamycin + TazaroteneBenzoyl Peroxide/Clindamycin + Vehicle CreamBenzoyl Peroxide Gel + TazaroteneClindamycin Gel + TazaroteneVehicle Gel + TazaroteneVehicle Gel + Vehicle CreamTotal
American Indian or Alaska Native1000001
Asian814569547
Black23162415148100
Multiracial1011988551
Native Hawaiian or Other Pacific Islander1110104
White636368797437384
08

Study locations

16 sites
  • Dermatology Research of Arkansas
    Little Rock, Arkansas 72205, United States
  • Center for Dermatology Cosmetic and Laser Surgery
    Fremont, California 94538, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Boulder Medical Center, P.C.
    Boulder, Colorado 80304, United States
  • Dermatology Associates Research
    Coral Gables, Florida 33134, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Callender Center for Clinical Research
    Mitchellville, Maryland 20721, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • University of North Carolina Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • MS Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Rivergate Dermatology & Skin Care Center
    Goodlettsville, Tennessee 37072, United States
  • The Skin Wellness Center, PC
    Knoxville, Tennessee 37922, United States
  • Dermatology Treatment & Research Center
    Dallas, Texas 75230, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 8 years after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2008
First posted
Jul 11, 2008
Start
Jun 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results delay requested
Sep 7, 2010
Results first posted
Mar 6, 2017
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00713609
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 11, 2008
Start date
Jun 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Mar 6, 2017
Last update
Mar 6, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benzoyl Peroxide · Clindamycin · Tazarotene

Start the discussion